Literature DB >> 20425475

Sclerosing cholangitis: pediatric perspective.

Nanda Kerkar1, Tamir Miloh.   

Abstract

Sclerosing cholangitis is a rare progressive cholestatic liver disease affecting the biliary tract. It may be associated with other diseases including autoimmune hepatitis, immunodeficiencies, cystic fibrosis, and sickle cell disease. Sclerosing cholangitis not associated with other diseases is termed "primary sclerosing cholangitis," which has a strong association with male gender, Caucasian race, and inflammatory bowel disease. Diagnosis is based on typical biochemical, radiologic, and histologic features. Medical management is directed mainly at managing complications (pruritus, cholangitis, strictures, and nutritional deficiencies). Administration of ursodeoxycholic acid results in biochemical improvement, but has not been proven to prolong transplant-free survival. Patients with autoimmune overlap respond to immunosuppression. The disease is typically progressive and evolves to biliary cirrhosis and possibly cholangiocarcinoma. Orthotopic liver transplantation remains the only life-extending alternative for patients with sclerosing cholangitis, with good long-term patient and graft survival, and recurrent graft primary sclerosing cholangitis in about 10% of children.

Entities:  

Mesh:

Year:  2010        PMID: 20425475     DOI: 10.1007/s11894-010-0104-5

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  32 in total

1.  Clinical spectrum of X-linked hyper-IgM syndrome.

Authors:  J Levy; T Espanol-Boren; C Thomas; A Fischer; P Tovo; P Bordigoni; I Resnick; A Fasth; M Baer; L Gomez; E A Sanders; M D Tabone; D Plantaz; A Etzioni; V Monafo; M Abinun; L Hammarstrom; T Abrahamsen; A Jones; A Finn; T Klemola; E DeVries; O Sanal; M C Peitsch; L D Notarangelo
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

2.  Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.

Authors:  Darrell S Pardi; Edward V Loftus; Walter K Kremers; Jill Keach; Keith D Lindor
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

Review 3.  Surgical pathology of the syndrome of primary sclerosing cholangitis.

Authors:  J Ludwig
Journal:  Am J Surg Pathol       Date:  1989       Impact factor: 6.394

Review 4.  Epidemiology of primary sclerosing cholangitis.

Authors:  E Schrumpf; K M Boberg
Journal:  Best Pract Res Clin Gastroenterol       Date:  2001-08       Impact factor: 3.043

5.  Primary sclerosing cholangitis in children: a histologic follow-up study.

Authors:  L Arturo Batres; Pierre Russo; Mark Mathews; David A Piccoli; Emil Chuang; Eduardo Ruchelli
Journal:  Pediatr Dev Pathol       Date:  2005-10-07

6.  Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis.

Authors:  Liesbet Henckaerts; Martine Jaspers; Werner Van Steenbergen; Liesbet Vliegen; Johan Fevery; Hilde Nuytten; Tania Roskams; Paul Rutgeerts; Jean-Jacques Cassiman; Séverine Vermeire; Harry Cuppens
Journal:  J Hepatol       Date:  2008-10-07       Impact factor: 25.083

7.  Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation.

Authors:  Jacob Alexander; James D Lord; Matthew M Yeh; Carlos Cuevas; Ramasamy Bakthavatsalam; Kris V Kowdley
Journal:  Liver Transpl       Date:  2008-02       Impact factor: 5.799

8.  Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis.

Authors:  R H Wiesner; P M Grambsch; E R Dickson; J Ludwig; R L MacCarty; E B Hunter; T R Fleming; L D Fisher; S J Beaver; N F LaRusso
Journal:  Hepatology       Date:  1989-10       Impact factor: 17.425

9.  Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.

Authors:  Yinka K Davies; Kathleen M Cox; Bisher A Abdullah; Anca Safta; Annie B Terry; Kenneth L Cox
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-07       Impact factor: 2.839

10.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Jill Keach; Jody Mooney; Carol Sargeant; Julie Braaten; Tamara Bernard; Debra King; Ellen Miceli; Jeff Schmoll; Tanya Hoskin; Prabin Thapa; Felicity Enders
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

View more
  5 in total

Review 1.  Persistent hypertransaminasemia in asymptomatic children: a stepwise approach.

Authors:  Pietro Vajro; Sergio Maddaluno; Claudio Veropalumbo
Journal:  World J Gastroenterol       Date:  2013-05-14       Impact factor: 5.742

Review 2.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

Review 3.  Child with Jaundice and Pruritus: How to Evaluate?

Authors:  Barath Jagadisan; Anshu Srivastava
Journal:  Indian J Pediatr       Date:  2016-03-02       Impact factor: 1.967

Review 4.  Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency.

Authors:  Shradha Agarwal; Lloyd Mayer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-03-13       Impact factor: 11.382

5.  Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents.

Authors:  Claudia Patricia Rojas; Rajasekhar Bodicharla; German Campuzano-Zuluaga; Lina Hernandez; Maria Matilde Rodriguez
Journal:  Fetal Pediatr Pathol       Date:  2014-04-22       Impact factor: 0.958

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.